HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Inhibition of interleukin-1beta-induced group IIA secretory phospholipase A2 expression by peroxisome proliferator-activated receptors (PPARs) in rat vascular smooth muscle cells: cooperation between PPARbeta and the proto-oncogene BCL-6.

Abstract
The inflammation that occurs during atherosclerosis is characterized by the release of large amounts of group IIA secretory phospholipase A2 (sPLA2-IIA). This study was designed to define the function of the three peroxisome proliferator-activated receptors (PPARs) on sPLA2 expression in vascular smooth muscle cells (VSMCs). We found that PPAR ligands decreased sPLA2-IIA activity and inhibited mRNA accumulation under inflammatory conditions. Furthermore, interleukin-1beta-induced sPLA2-IIA promoter activity was inhibited by the three PPAR ligands and in a similar way when cells were cotransfected with PPARalpha, PPARbeta, or PPARgamma, plus retinoid X receptor alpha (RXRalpha). Our study revealed that the regulation of sPLA2-IIA gene transcription by PPARalpha/RXR and PPARgamma/RXR heterodimers requires an interaction with a PPAR response element (PPRE) of the sPLA2-IIA promoter. In contrast, PPARbeta operates through a PPRE-independent mechanism. In addition, we demonstrated that VSMCs expressed the transcriptional repressor BCL-6. Overexpression of BCL-6 markedly reduced sPLA2-IIA promoter activity in VSMCs, while a dominant negative form of BCL-6 abrogated sPLA2 repression by PPARbeta. The PPARbeta agonist induced a BCL-6 binding to the sPLA2 promoter in VSMCs under inflammatory conditions. The knockdown of BCL-6 by short interfering RNA abolished the inhibitory effect of the PPARbeta ligand on sPLA2 activity and prostaglandin E2 release. Thus, the inhibition of sPLA2-IIA activity by PPARbeta agonists may provide a promising approach to impacting the initiation and progression of atherosclerosis.
AuthorsLucas Ravaux, Chantal Denoyelle, Claire Monne, Isabelle Limon, Michel Raymondjean, Khadija El Hadri
JournalMolecular and cellular biology (Mol Cell Biol) Vol. 27 Issue 23 Pg. 8374-87 (Dec 2007) ISSN: 1098-5549 [Electronic] United States
PMID17908795 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Interleukin-1beta
  • Ligands
  • PPAR-beta
  • Proto-Oncogene Proteins c-bcl-6
  • RNA, Messenger
  • RNA, Small Interfering
  • Repressor Proteins
  • Retinoid X Receptors
  • Group II Phospholipases A2
Topics
  • Animals
  • Cattle
  • Enzyme Induction (drug effects)
  • Gene Expression Regulation, Enzymologic (drug effects)
  • Group II Phospholipases A2 (biosynthesis, genetics)
  • Interleukin-1beta (pharmacology)
  • Ligands
  • Male
  • Muscle, Smooth, Vascular (cytology, drug effects, enzymology)
  • Myocytes, Smooth Muscle (drug effects, enzymology)
  • PPAR-beta (metabolism)
  • Protein Binding (drug effects)
  • Proto-Oncogene Proteins c-bcl-6 (metabolism)
  • RNA, Messenger (genetics, metabolism)
  • RNA, Small Interfering (metabolism)
  • Rats
  • Rats, Wistar
  • Repressor Proteins (metabolism)
  • Response Elements
  • Retinoid X Receptors (metabolism)
  • Sequence Deletion

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: